Full Text View
Tabular View
No Study Results Posted
Related Studies
IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer
This study is ongoing, but not recruiting participants.
First Received: July 8, 2002   Last Updated: May 9, 2009   History of Changes
Sponsor: Royal Marsden - London
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00041223
  Purpose

RATIONALE: IH636 grape seed extract may lessen hardening of breast tissue caused by radiation therapy and may help patients live more comfortably.

PURPOSE: Randomized phase II trial to study the effectiveness of IH636 grape seed extract in treating hardening of breast tissue in women who have undergone radiation therapy for early breast cancer.


Condition Intervention Phase
Breast Cancer
Radiation Fibrosis
 Dietary Supplement: IH636 grape seed proanthocyanidin extract
 Phase II

Study Type: Interventional
Study Design: Supportive Care, Randomized, Double-Blind, Placebo Control
Official Title: Double-Blind, Placebo-Controlled, Randomized Phase II Trial of IH636 Grape Seed Proanthocyanidin Extract (GSPE) in Patients With Adverse Effects of High Dose Breast Radiotherapy

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: September 2002
Detailed Description:

OBJECTIVES:

  • Determine the efficacy of IH636 grape seed proanthocyanidin extract for the treatment of radiation-induced fibrosis after high-dose radiotherapy in women with a history of early breast cancer.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to time since prior radiotherapy. Patients are randomized to 1 of 2 arms.

  • Arm I: Patients receive oral IH636 grape seed proanthocyanidin extract three times daily for 6 months.
  • Arm II: Patients receive an oral placebo three times daily for 6 months. Patients are followed at 6 months.

PROJECTED ACCRUAL: A total of 72 patients (48 for arm I and 24 for arm II) will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • History of early breast cancer

    • T1-T3, N0-N1, M0
  • No evidence of cancer recurrence
  • Palpable breast induration due to prior radiotherapy

  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Sex:

  • Female

Menopausal status:

  • Not specified

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • Not specified

Hepatic:

  • Not specified

Renal:

  • Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine therapy:

  • Not specified

Radiotherapy:

  • See Disease Characteristics
  • At least 2 years since prior radiotherapy

Surgery:

  • Not specified

Other:

  • At least 3 months since prior dietary supplementation containing IH636 grape seed proanthocyanidin extract over 50 mg per day
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00041223

Locations
United Kingdom, England
Royal Marsden Hospital
Sutton, England, United Kingdom, SM2 5PT
Sponsors and Collaborators
Royal Marsden - London
Investigators
Study Chair: John R. Yarnold, MD, FRCR Royal Marsden - Surrey
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers: CDR0000069454, RMNHS-GRAPE-1991, RMNHS-1991, EU-20209
Study First Received: July 8, 2002
Last Updated: May 9, 2009
ClinicalTrials.gov Identifier: NCT00041223     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
radiation fibrosis
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer

Additional relevant MeSH terms:
Anti-Infective Agents
Antiprotozoal Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Fibrosis
Physiological Effects of Drugs
Disorders of Environmental Origin
Antiparasitic Agents
Pathologic Processes
Neoplasms by Site
Respiratory Tract Diseases
Procyanidin
Therapeutic Uses
 Breast Diseases
Lung Diseases, Interstitial
Skin Diseases
Wounds and Injuries
Breast Neoplasms
Protective Agents
Pharmacologic Actions
Neoplasms
Proanthocyanidin
Lung Diseases
Radiation Pneumonitis
Radiation Injuries

ClinicalTrials.gov processed this record on November 09, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services